quinazolines has been researched along with tak 285 in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ding, X; Li, Y; Mao, W; Meng, X; Tang, H; Wang, X; Xie, S; Yang, H | 1 |
| Birkeland, AC; Bradford, CR; Brenner, JC; Carey, TE; Foltin, SK; Komarck, CM; Ludwig, ML; Mann, JE; McHugh, JB; Michmerhuizen, NL; Prince, ME; Sandelski, MM; Scott, MV; Spector, ME; Tillman, BN; Yanik, M | 1 |
| Bello, M; Correa-Basurto, J; García, B; Saldaña-Rivero, L; Sánchez-Espinosa, VA | 1 |
3 other study(ies) available for quinazolines and tak 285
| Article | Year |
|---|---|
Drug response to HER2 gatekeeper T798M mutation in HER2-positive breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Bridged Bicyclo Compounds, Heterocyclic; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Hydroxybutyrates; Lapatinib; Molecular Dynamics Simulation; Mutation; Protein Kinase Inhibitors; Purines; Quinazolines; Receptor, ErbB-2; Staurosporine | 2016 |
Identification of Targetable ERBB2 Aberrations in Head and Neck Squamous Cell Carcinoma.
Topics: Blotting, Western; Bridged Bicyclo Compounds, Heterocyclic; Carbamates; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Enzyme Inhibitors; ErbB Receptors; Gene Expression Profiling; Humans; Hydroxybutyrates; Immunohistochemistry; Laryngeal Neoplasms; Mouth Neoplasms; Mutation; Purines; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Triazines | 2016 |
Structural and energetic basis for the molecular recognition of dual synthetic vs. natural inhibitors of EGFR/HER2.
Topics: Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Cell Proliferation; Dimerization; ErbB Receptors; Humans; Hydroxybutyrates; Lapatinib; Molecular Dynamics Simulation; Neoplasms; Phosphorylation; Protein Conformation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction | 2018 |